Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis

Australian and New Zealand Journal of Psychiatry

Volumn 45, Issue 9, 2011, Pages 740-748

  Thompson, Andrew ^a,b   Hetrick, Sarah E ^b   Álvarez Jiménez, Mario ^b   Parker, Alexandra G ^b   Willet, Michaela ^b   Hughes, Frank ^a,b   Gariup, Maria ^c   Gomez, David Lopez ^d   McGorry, Patrick D ^a,b  

^a THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antipsychotic medications; Implementation; Metabolic monitoring

Indexed keywords

GLUCOSE; LIPID; NEUROLEPTIC AGENT;

ADOLESCENT; ARTICLE; BLOOD PRESSURE MONITORING; COMPARATIVE STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTERVIEW; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL SERVICE; METABOLIC DISORDER; METABOLIC PARAMETERS; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PREVENTION STUDY; PSYCHOSIS; SCREENING TEST; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT CONTROL; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; OVERWEIGHT; PSYCHOTIC DISORDERS; WEIGHT GAIN;

EID: 80052512501     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048674.2011.595370     Document Type: Article

References (43)

1. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36:239-245.
2. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007; 68:4-7.
3. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 492-501.
4. Nasrallah H, Meyer J, Goff D et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86;15-22.
5. Daumit GL, Pronovost PJ, Anthony CB, Guallar E, Steinwachs DM, Ford DE. Adverse events during medical and surgical hospi-talizations for persons with schizophrenia. Arch Gen Psychiatry 2006; 63:267-272.
6. Álvarez-Jiménez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Hetrick S, Rodriguez-Sanchez JM, Crespo-Facorro B. Antipsy-chotic-induced weight gain in schizophrenia spectrum disorders: a systematic critical reappraisal. CNS Drugs 2008; 22:547-562.
7. Tschoner A, Engl J, Laimer M, Kaser et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007; 61:1356-1370.
8. Newcomer J W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19:S1-93.
9. Newcomer J W, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007; 298:1794-1796.
10. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsy-chotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765-1773.
11. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66:51-57.
12. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106:286-290.
13. Angermeyer MC, Matschisger H. Neuroleptics and quality of life: a patient survey. Psychiatr Prax 2000; 27:64-68.
14. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004; 65:13-26.
15. Zipursky RB, Gu H, Green AI et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187:537-543.
16. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry, 2011; 68:609-616.
17. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163:2072-2079.
18. Alvarez-Jiménez M, González-Blanch C, Vázquez- Barquero JL et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-na ï ve first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006; 67:1253-1260.
19. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008; 193:101-107.
20. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; 1:CD005148.
21. Cohn TA, Sernyak MJ. Metabolic monitoring of patients treated with antipsychotic medications. Can J Psychiatry 2006; 51:492-501.
22. Lambert TJR, Chapman LH, on behalf of the Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181:544-548.
23. Barnes TRE, Paton C, Cavanagh M-R, Hancock E, Taylor DM, on behalf of the UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychot-ics in community patients. Schizophr Bull 2007; 33:1397-1403.
24. Morrato EH, Druss B, Hartung DM e t al. Metabolic testing rates in three state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67:17-24.
25. Walter G, Delaroche A, Soh N e t al. Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australas Psychiatry 2008; 16:253-262.
26. Crabb J, McAllister M, Blair A. Who should swing the stethoscope? An audit of baseline physical examination and blood monitoring on new patients accepted by an early intervention in psychosis team. Early Interv Psychiatry 2009; 3:312-316.
27. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001; 39:II-46-II-54.
28. Killackey E, Jorm A, Alvarez-Jimenez M, McCann T V, Hides L, Couineau AL. Do we do what we know works, and if not why not? Aust N Z Psychiatry 2008; 42:439-444.
29. Grimshaw JM, Thomas RE, MacLennan G et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004; 8:iii-iv, 1-72.
30. Grol R. Personal paper: beliefs and evidence in changing clinical practice. BMJ 1997; 315:418-421.
31. Baker R, Camosso-Stefinovic J, Gillies C, et al. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. Cochrane Database of Syst Rev 2010; 3:CD005470.
32. Morrato EH, Newcomer J W, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009; 32:1037-1042.
33. Barnes TRE, Paton C, Hancock E, Cavanagh MR, Taylor D, Lelliott P. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand 2008; 118:26-33.
34. Lambert TJ, Newcomer J W. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009; 190:S39-42.
35. Waterreus AJ, Laugharne JD. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 2009; 190:185-189.
36. Edwards, J, Harris, M, Herman, A. The Early Psychosis Prevention and Intervention Centre Melbourne Australia: An overview November 2001. In: Ogura C, ed. Recent advances in early intervention and prevention in psychiatric disorders. Tokyo: Seiwa-Shoten, 2002:26-33.
37. Hetrick S, Alvarez-Jimenez M, Parker A et al. Promoting physical health in youth mental health services: ensuring routine monitoring of weight and metabolic indices in a first episode psychosis clinic. Australas Psychiatry 2010; 18:451-455.
38. Batscha C, Schneiderhan ME, Kataria Y, Rosen C, Marvin RW. Treatment settings and metabolic monitoring for people experiencing first-episode psychosis. J Psychosoc Nurs Ment Health Serv 2010; 48:44-49.
39. Mackin P, Bishop D, Watkinson H. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 2007; 7:28.
40. Dunbar L, Wheeler A, Harrison J et al. Implementing metabolic risk assessment in a secondary care mental health service. Aus-tralas Psychiatry 2010; 18:318-321.
41. McGorry P, Tanti C, Stokes R et al. headspace: Australia's national youth mental health foundation-where young minds come first. Med J Aust 2007; 187:S68-70.
42. Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman A. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database of Syst Rev 2006; 2:CD000259.
43. Foley D, Morley K, Carroll K, Moran J, McGorry P, Murphy B. Successful implementation of cardiometabolic monitoring of patients treated with antipsychotics. Med J Aust 2009; 191:518-519.